Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 11, 1998

View Archived Issues

Genzyme Tissue Repair: Q3 1998 highlights

Gliatech: Q3 1998 highlights

NeoRx announces license agreement with Angiotech

AltaRex seeks permission to study immunological activity of OvaRex in phase II trial

Nonpeptide CRF1 antagonist developed at Parke-Davis modulates brain NE levels

ATTRACT study establishes efficacy, safety of infliximab in RA patients

European phase III trial of Macritonin produces positive analysis of one-year BMD data

LY-300164 protects against kainate-induced neurotoxicity in vitro in a stereoselective manner

Chiron initiates phase II testing of rFGF-2

Positive phase II results reported for potential asthma treatment

Synthelabo presents in vitro, ex vivo and in vivo data on new MAO-B inhibitor

Unexpected adverse events encountered with bosentan in REACH-1 trial

Chugai describes inhibitors of iNOS, nNOS

Selective inhibitors of vascular wall, microsomal ACAT developed at Kowa

Nicotinic acetylcholine receptor ligands for nicotine addiction and CNS disorders

Pyridyl compounds claimed by Astra for the Rx of asthma and rhinitis

Proton pump inhibitors in the pipeline at Yuhan

PD-161989: novel AMPA/GLYN receptor antagonist related to PNQX

RenaGel available this month in the U.S.

Synthelabo presents new 5-HT1A inverse agonist with antagonist and anxiolytic-like activity in vivo

New anticancer drug candidate revealed by Sugen; product enters phase I testing in U.K.

Neuroprotective effects of NCC-161, a new neuronal calcium antagonist

European filing announced for Enbrel

Photoangioplasty with Antrin reduces atherosclerotic plaque in rabbit models

Inhibition of cytokine production contributes to the antiinflammatory activity of orazipone

Cytel's VLA4 antagonist shows potential for treating allergic lung inflammation

First clinical trial of oral neurophilin compound in patients with diabetic neuropathy

Improved dosage form of selegiline now on the U.K. market

Radiopharmaceutical for chronic knee synovitis in development at British university

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...